RNA Jan 2025 35.000 call
| Previous close | 4.2000 |
| Open | 4.2000 |
| Bid | 10.3000 |
| Ask | 13.9000 |
| Strike | 35.00 |
| Expiry date | 2025-01-17 |
| Day's range | 4.2000 - 4.2000 |
| Contract range | N/A |
| Volume | |
| Open interest | 4 |
PR NewswireAvidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that on June 20, 2024, the Human Capital Management Committee of Avidity's Board of Directors granted non-qualified stock option awards to purchase an aggregate of 173,300 shares of its common stock and 86,650 restricted stock units ("RSUs") to fourteen (14) new non-executive employees under the Avidity Bi
- PR Newswire
Avidity Biosciences Partners with the FSHD Society to Raise Awareness of Facioscapulohumeral Muscular Dystrophy on World FSHD Day
Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced it is partnering with the FSHD Society and joining the global community of patients, caregivers, and healthcare providers to raise awareness of facioscapulohumeral muscular dystrophy in support of World FSHD Day. The FSHD Society is hosting a webinar with Avidity today at 1:00 p.m. ET to share recent unpre
Simply Wall St.Estimating The Intrinsic Value Of Avidity Biosciences, Inc. (NASDAQ:RNA)
Key Insights The projected fair value for Avidity Biosciences is US$46.34 based on 2 Stage Free Cash Flow to Equity...
